Counting, analysing and reporting exacerbations of COPD in randomised controlled trials. - Wikidata - wikimedia - TriplyDB

Counting, analysing and reporting exacerbations of COPD in randomised controlled trials.

Counting, analysing and reporting exacerbations of COPD in randomised controlled trials.

http://www.wikidata.org/entity/Q36912026

about

Long-acting beta 2 -agonists and long-acting muscarinic antagonists in a combined inhaler versus either agent alone or placebo for chronic obstructive pulmonary disease Prevention of acute exacerbations of COPD: American College of Chest Physicians and Canadian Thoracic Society Guideline.Pharmacological strategies to reduce exacerbation risk in COPD: a narrative review Evidence synthesis for count distributions based on heterogeneous and incomplete aggregated data.Do alternative methods for analysing count data produce similar estimates? Implications for meta-analyses.ICE COLD ERIC--International collaborative effort on chronic obstructive lung disease: exacerbation risk index cohorts--study protocol for an international COPD cohort study.Action Plan to enhance self-management and early detection of exacerbations in COPD patients; a multicenter RCT Intent-to-treat analysis in the presence of off-treatment or missing data.Variability of the chronic obstructive pulmonary disease key epidemiological data in Europe: systematic review.Treatment adherence and health outcomes in patients with bronchiectasis.Inhaled corticosteroids in chronic obstructive pulmonary disease: a pro-con perspective.Detecting exacerbations using the Clinical COPD Questionnaire Daily step count predicts acute exacerbations in a US cohort with COPD.Putting health status guided COPD management to the test: protocol of the MARCH study.Moxifloxacin versus amoxicillin/clavulanic acid in outpatient acute exacerbations of COPD: MAESTRAL results.The role of bronchodilator treatment in the prevention of exacerbations of COPD.Comprehensive self management and routine monitoring in chronic obstructive pulmonary disease patients in general practice: randomised controlled trial β-Blockers for the prevention of acute exacerbations of chronic obstructive pulmonary disease (βLOCK COPD): a randomised controlled study protocol Budesonide/formoterol as effective as prednisolone plus formoterol in acute exacerbations of COPD. A double-blind, randomised, non-inferiority, parallel-group, multicentre study.Study design considerations in a large COPD trial comparing effects of tiotropium with salmeterol on exacerbations.Long-Term Effects of an Internet-Mediated Pedometer-Based Walking Program for Chronic Obstructive Pulmonary Disease: Randomized Controlled Trial.Insights into interventions in managing COPD patients: lessons from the TORCH and UPLIFT studies Role of Tiotropium in Reducing Exacerbations of Chronic Obstructive Pulmonary Disease When Combined With Long-Acting β2 -Agonists and Inhaled Corticosteroids: The OUTPUL Study An official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice.Preventing and managing exacerbations in COPD--critical appraisal of the role of tiotropium.Frequent chronic obstructive pulmonary disease exacerbators: how much real, how much fictitious?The impact of psychological distress on exacerbation rates in COPD.Pharmacotherapies for chronic obstructive pulmonary disease: a multiple treatment comparison meta-analysis.Do we know the minimal clinically important difference (MCID) for COPD exacerbations?Comparative effectiveness of long term drug treatment strategies to prevent asthma exacerbations: network meta-analysis.Defining exacerbations in chronic obstructive pulmonary disease.Long-acting muscarinic antagonists vs. long-acting β 2 agonists in COPD exacerbations: a systematic review and meta-analysis.Predictors of future exacerbation risk in patients with asthma.Duration of Hospitalization and Lung Function Deterioration as Predictors of Future Chronic Obstructive Pulmonary Disease Exacerbations.Misspecification of at-risk periods and distributional assumptions in estimating COPD exacerbation rates: The resultant bias in treatment effect estimation.Reduced COPD exacerbation risk correlates with improved FEV1: A meta-regression analysis.Clinical and pharmacoeconomic profile of COPD patients with FEV1 50--60% predicted: pilot study on the impact of the extended indication of ICS/LABA.Prospective outcomes in patients with acute exacerbations of chronic obstructive pulmonary disease presenting to hospital: a generalisable clinical audit.Prevention of Exacerbations in Chronic Obstructive Pulmonary Disease: Knowns and Unknowns.Effect of an integrated care programme on re-hospitalization of patients with chronic obstructive pulmonary disease.

P2860

Q24194044-DDE33D32-C864-420C-9688-5163ECFC6EFD Q27348844-6086BF67-970C-4EE8-AC19-73E794B7AFEA Q28070274-148A7E59-F28C-48DE-B752-F5A02BC191AB Q30949429-751F2159-8CBE-47F4-B450-5FC9C0894E52 Q31024883-A2167236-301F-48F2-8452-710CA86C1F60 Q33440006-CCC2736E-024C-4969-B24C-802B3C11AB4C Q33521100-C9907166-41EC-4ED9-AD01-B5E7D92BA746 Q33536518-3E572491-EAA2-4BDF-8507-67447FF14E90 Q33796149-7D00719A-A368-43B7-B631-FB09F24C7664 Q33877099-3F67C38B-6392-483B-BB5E-36DCDFDCC61D Q34065276-1B8EE668-9F30-493B-AE3F-431770D43583 Q34174389-A85D87C9-4EBF-43F3-A78B-B340E73CE829 Q34673119-98AAEF40-2319-4B86-AB3B-CCD1818E3FBB Q34798279-F7EA96F7-EA0B-423D-9140-95AAE880EA4E Q36087058-CD9DF126-CC82-4343-9DC1-446865D4E016 Q36438669-7259333D-893C-484B-A548-164CE9324B4A Q36444402-19C96362-FF09-4A5F-A1E4-8F0722640E3A Q37006972-F31D0BF4-C4D0-4E46-B4AA-620AD25D5D8D Q37122668-FE631B12-2F87-4862-81F4-5B4A30CBB5F0 Q37168340-B2C60751-AEBB-41F6-9368-84FD8B6CC16C Q37195122-F86D2FB9-8713-4465-9949-DC7CD6B728EE Q37199668-D5160809-25EC-429B-915E-1CE52EF8FD93 Q37418094-6E26F8A4-42FE-4594-87C8-5F90670FFC72 Q37522916-D4937254-3B73-40B0-A50B-E0EDF3C8E86C Q37724621-D1BBD44E-38C1-4354-A43A-BD0D479FACB4 Q37776725-A4EAE5F6-07C2-444B-9231-49E2CF750AE4 Q37808057-D7033D6C-1D79-4331-BCD5-267D0A2F5420 Q37864538-8C3044D8-6D68-49AB-9FDE-10A2B86C6051 Q38091512-E89B3547-66B0-4883-8121-E42E3EA60A48 Q38219526-8FD104FB-905C-48D2-9448-5751BFB86565 Q38503383-274D5DAB-3525-4E25-821B-C44C61BD4B87 Q38646619-82F60693-B3FE-4184-9FA9-223F59D54BCF Q38834113-53B5DB47-0ED7-4C6E-9329-565BBB6278F0 Q38895033-26C1842B-8DF2-4D02-94C7-604D39473E5F Q39102942-BE2621FC-00FD-4717-8233-8A8ED225E7A7 Q39292087-90BF62A3-1D9C-486D-9711-0CAE48EE72BC Q39979584-C76D704B-4F16-4F0C-8DFD-6895560C934C Q40902551-C43C49F7-5327-4C4E-8070-BD9CAE0C16C8 Q41400495-86C90403-AC0B-44D6-8758-ABEB4634D33A Q45122322-C9392AC1-1C14-42F9-940A-339589E65CA3

P2860

Counting, analysing and reporting exacerbations of COPD in randomised controlled trials.

http://www.wikidata.org/entity/Q36912026

description

2007 nî lūn-bûn

@nan

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

2007年论文

@zh

2007年论文

@zh-cn

name

Counting, analysing and reporting exacerbations of COPD in randomised controlled trials.

@en

type

label

Counting, analysing and reporting exacerbations of COPD in randomised controlled trials.

@en

prefLabel

Counting, analysing and reporting exacerbations of COPD in randomised controlled trials.

@en

P1433

Q36912026-E47BA991-1256-4C81-BF0A-F49371D3C51A

P1476

Q36912026-C218AD12-4BCE-424C-81E3-09295DA419C2

P2093

Q36912026-1BA2A583-F318-4C5C-BDD3-C09B1129F152

Q36912026-25F9D8B5-EA23-467E-BFDD-7DDCAF8279DF

Q36912026-28423BFE-608F-42D0-8266-9EF069B1D433

Q36912026-6ADF4228-E3E7-4278-AA4B-F2900869E75B

Q36912026-90396B49-059C-46C4-BF1D-7B3B85D99201

Q36912026-91BEC2C8-A6A5-492F-B00B-EFCD47226A14

Q36912026-A234DA2D-5FD0-4448-95B2-FE895F2795E5

Q36912026-A3E0B2C6-BD7B-4C37-9CB4-9B601C8FDA6B

Q36912026-B322A2BF-4B76-4315-A992-0F518120E65F

Q36912026-F23921A4-DB44-436F-B401-053D01517E3E

P304

Q36912026-741620E1-5A31-4595-95E7-B0E80046E03A

P31

Q36912026-49979ab8-a883-4704-a7a9-fa16748be880

Q36912026-912B731D-C5E1-4657-A201-0786941C5520

P356

Q36912026-AB142BD9-A0BD-41DA-A67C-8F11B23E5F57

P407

Q36912026-E73E28FE-D3B9-4E71-A6AC-EF2CDAD636EB

P433

Q36912026-1D85FE47-2ED9-4DD0-8E1A-7899DAC221C7

P478

Q36912026-1F61C606-FD0B-4658-9334-C4D9765B9151

P50

Q36912026-743D43B8-D081-4EC2-9B7D-8E59F20A4598

Q36912026-7A57714F-8880-40F0-960B-603188E4859B

Q36912026-820933D1-807F-4E32-9EFB-AE7431D9B7B2

P577

Q36912026-CA30DF96-0CAB-4530-B3B8-8771F66AA37C

P698

Q36912026-14552ECC-15F6-4B98-87B5-85E2A94A752F

P921

Q36912026-C9C6D95E-D524-45B3-8D44-1C4599204873

P356

THX.2007.082636

P1433

P1476

Counting, analysing and reporting exacerbations of COPD in randomised controlled trials

@en

P2093

Canadian Thoracic Society/Canadian Respiratory Clinical Research Consortium

http://www.w3.org/2001/XMLSchema#string

D O'Donnell

http://www.w3.org/2001/XMLSchema#string

F Maltais

http://www.w3.org/2001/XMLSchema#string

J F Bourbeau

http://www.w3.org/2001/XMLSchema#string

K L Vandemheen

http://www.w3.org/2001/XMLSchema#string

M Balter

http://www.w3.org/2001/XMLSchema#string

M Fitzgerald

http://www.w3.org/2001/XMLSchema#string

R S Goldstein

http://www.w3.org/2001/XMLSchema#string

S Doucette

http://www.w3.org/2001/XMLSchema#string

S Suissa

http://www.w3.org/2001/XMLSchema#string

P304

122-128

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/THX.2007.082636

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

63

http://www.w3.org/2001/XMLSchema#string

P50

Dean A Fergusson

P577

2007-08-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

17702790

http://www.w3.org/2001/XMLSchema#string

P921

chronic obstructive pulmonary disease